Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement

Russell, Linda; Craig, Chad M.; Flores, Eva K.; Wainaina, J Njeri; Keshock, Maureen; Kasten, Mary J.; Hepner, David L.; Edwards, Angela F.; Urman, Richard D.; Mauck, Karen F.; Oprea, Adriana D.

doi:10.1016/j.mayocp.2022.05.002

Cited by 7 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF-α plays a critical role in recruitment of inflammatory cells required for tissue repair, and treatment with TNF inhibitors may result in an increased risk of infection, impaired or delayed wound healing, [ 94 ] thus preoperative biologic discontinuation is recommended to minimize the risk of surgery related infection. It is recommended that surgery should be performed after biologic discontinuation for a regular dosing interval.…”

Section: Consensusmentioning

confidence: 99%

“…As there is no data available for perioperative use of IL-17A inhibitors, ustekinumab and guselkumab, preoperative discontinuation of these medications are recommended due to concern for infection and poor wound healing. [ 94 ] It is recommended to discontinue tofacitinib for 3 days before surgery. For SpA patients with a previous history of prosthetic joint infection related to tofacitinib use, JAK inhibitor use is not recommended peri-operatively.…”

Section: Consensusmentioning

confidence: 99%

See 1 more Smart Citation

Consensus on targeted drug therapy for spondyloarthritis

Tian,

Li,

Liu

et al. 2023

Rheumatology and Immunology Research

View full text Add to dashboard Cite

Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and they are becoming increasingly important in the treatment of SpA. However, identifying the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these “targeted therapeutic drugs”. Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), managed by Peking Union Medical College Hospital, the “Consensus on targeted drug therapy for spondyloarthritis” has been developed in collaboration with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, and Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus has been developed with evidence-based methodology and has followed the international standard for consensus development.

show abstract

Section: Consensusmentioning

confidence: 99%

Section: Consensusmentioning

confidence: 99%